There were 457 press releases posted in the last 24 hours and 202,527 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Merck Announces Presentation of Phase 2 Results for MK-7264, an Investigational, P2X3 Receptor Antagonist, Being Evaluated for the Treatment of Chronic Cough

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image